标题:Receptor tyrosine kinase alterations and therapeutic opportunities in squamous cell carcinoma of the lung
作者:Wang,D.;Du,L.;Liu,Q.;Liu,X.;Wang,Z.
作者机构:[Wang, D] Shandong Provincial Hospital Affiliated to Shandong University, 324 Jing Wu Road, Jinan 250021 Shandong, China;[ Du, L] Shandong Provincial 更多
通讯作者:Wang, Z
通讯作者地址:[Wang, Z]Shandong Univ, Shandong Prov Hosp, 324 Jing Wu Rd, Jinan 250021, Shandong, Peoples R China.
来源:Cancer Chemotherapy and Pharmacology
出版年:2013
卷:72
期:4
页码:725-731
DOI:10.1007/s00280-013-2252-4
关键词:Molecular-targeted therapy;Receptor tyrosine kinase;Squamous cell carcinoma of the lung
摘要:Purpose: Targeted therapy has greatly improved the treatment for adenocarcinoma of the lung, but not squamous cell carcinoma (SCC) of the lung. The current paper describes the abnormalities of receptor tyrosine kinases (RTK) in lung SCC in a hope to stimulate the development of therapeutics that can have clinical impact. Methods: We reviewed both clinical and preclinical studies published in English regarding RTK abnormalities and/or RTK-targeting treatment for SCC of the lung. Results: RTK alterations have been demonstrated as biological signature for SCC of the lung. A number of clinical trials of RTK-targeting therapy have been carried out or are ongoing, with encouraging results. Conclusions: SCC of the lung should be treated as an independent disease with unique treatment options based on molecular changes, particularly RTK.
收录类别:SCOPUS;SCIE
WOS核心被引频次:1
Scopus被引频次:1
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84885373576&doi=10.1007%2fs00280-013-2252-4&partnerID=40&md5=0e44b7cc9c702f87d7d4beae90d27848
TOP